Phase 3 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a specific type of eye condition called choroidal neovascularization (abnormal blood vessel growth at the back of the eye) caused by age-related macular degeneration, including certain related conditions affecting the retina, in at least one eye — and who have not yet received any treatment for it
- People whose diagnosis of this wet form of age-related macular degeneration was confirmed within the last 21 days before starting the study treatment
Who may not be able to join:
- People with high blood pressure that is not under control at the time of their screening appointment
- People who have had laser treatment on the macula (a part of the retina) in the eye being studied
- People who have a history of eye inflammation (uveitis) in either eye
- People who have had cataract surgery, a certain type of glaucoma surgery, or a specific laser eye procedure (YAG laser capsulotomy) in the eye being studied within the past 90 days
- People with glaucoma (a condition causing pressure in the eye) that is not under control in the eye being studied
- People who have another active retinal condition in the eye being studied, beyond the condition this trial is looking at
- People who have previously received injections into the eye (such as anti-VEGF therapy or any other intravitreal treatment) in the eye being studied
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Australian sites
+61 2 9959 0053
+ 61 2 9635 7077
+61 2 9746 2988
+61 2 9382 7379
+61 2 9570 1522
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Mean Change in Best-Corrected Visual Acuity (BCVA) [Early Treatment of Diabetic Retinopathy Study (ETDRS Letters)] From Baseline to Year 1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.